<DOC>
	<DOCNO>NCT02182518</DOCNO>
	<brief_summary>The aim trial evaluate clinical efficacy safety Epinastine 10 mg + Pseudoephedrine 120 mg slow release ( SR ) administer twice day , compare Epinastine 10 mg alone administer twice daily .</brief_summary>
	<brief_title>Epinastine + Pseudoephedrine SR ( Slow Release ) Versus Epinastine Alone Patients With Perennial Allergic Rhinitis</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<mesh_term>Pseudoephedrine</mesh_term>
	<mesh_term>Ephedrine</mesh_term>
	<mesh_term>Epinastine</mesh_term>
	<criteria>Male female outpatient Over 12 year old Patients grant write informed consent , personally legal representative , part study accomplishment model informed consent approve Ethic Committee institution Patients establish diagnosis allergic perennial rhinitis clinical criterion ( allergic one allergen ) Patients moderate complete nasal blockage characterize ≥50 mm VAS parameter visit 1 2 Patients positive ( ≥3 mm compare negative control ) skin test ( `` Prick Test '' ) one follow allergen : Dermatophagoides pteronyssinus Dermatophagoides farinae Blomia tropicalis Alternaria alternata Cladosporium herbarum Aspergillus fumigatus Penicillium notatum cat 's fur dog 's fur Pregnant breast feed woman , woman without contraceptive method : postmenopausal period and/or submit bilateral tubal ligation hysterectomy and/or one follow contraceptive control : oral contraceptive IUD ( intrauterine device ) diaphragm Patients unable understand , accept follow protocol instruction History serious adverse event antihistamines Patients treatment calcium antagonist antihypertensive drug Patients treatment digitalis Patients treatment MAO ( monoamine oxidase ) inhibitors Patients treatment sympathicomimetics Patients receive follow drug period specify , visit 1 : Inhaled/Topics short act β2 agonist ( 12 hour ) long act β2 agonist ( 48 hour ) ipratropium bromide ( 12 hour ) nasal drop without vasoconstrictor ( 3 day ) DSCG ( disodium cromoglycate ) ( 3 day ) nedocromil ( 7 day ) nasal drops vasoconstrictor ( 7 day ) azelastine ( 14 day ) levocabastine ( 14 day ) corticosteroid ( 30 day ) corticosteroids site Prick test ( 3 month ) investigational drug ( 3 month ) Oral short act β2 agonist ( 18 hour ) short act theophylline ( 24 hour ) phenothiazine ( 48 hour ) long act theophylline ( 72 hour ) anticholinergic ( 7 day ) antihistamine ( except astemizole ) ( 7 day ) MAO ( monoamine oxidase ) inhibitor ( 14 day ) corticosteroid ( 30 day ) ketotifen ( 3 month ) imipramine ( 30 day ) astemizole ( 2 month ) investigational drug ( 3 month ) Parenteral aminophylline ( 24 hour ) phenothiazine ( 48 hour ) antihistamine ( 7 day ) corticosteroid ( 30 day ) imipramine ( 30 day ) investigational drug ( 3 month ) Patients desensitization therapy Patients therapy antibiotic Patients non compensate endocrine disease Patients atrophic rhinitis Patients rhinitis due acetylsalicylic acid Patients acute chronic infectious sinusitis Patients asthma , need treatment beta2 agonist twice per week Patients glaucoma Patients history renal and/or hepatic failure Patients know platelet dysfunction due disease drug ( purpura thrombocytopenic idiopathic , use anticoagulant , use antiplatelets drug ) Patients oncological disease Patients nasal septal deviation cause alteration nasal flux , polyp , anatomic/structural alteration ( ex. , tumor , leishmaniosis , etc . ) Patients cardiovascular disease Patients arterial hypertension Patients require halogenates anesthetic Patients diabetes mellitus Patients hyperthyroidism Patients prostatic hypertrophy Patients epilepsy seizure</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>